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S U M M A R Y
Objective: Early studies on blood donors point to a seroprevalence of approximately 0.25% for hepatitis C
virus (HCV) infection in Iran. However, the true prevalence in the general population is unknown. The
objective of this study was to determine the prevalence of HCV infection in the general population of
Iran.
Methods: We randomly selected 6583 subjects from three provinces in Iran for inclusion in the study.
Subjects were aged between 18 and 65 years. Anti-hepatitis C antibody was tested by a third-generation
ELISA test. A recombinant immunoblot assay (RIBA) test was used to conﬁrm the results. Risk factors
were recorded and a multivariate analysis was performed.
Results: A total of 5684 plasma samples were tested. After conﬁrmatory tests, we found 50 cases of HCV.
The overall weighted prevalence of anti-HCV was 0.5%. The rate was signiﬁcantly higher in men (1.0%)
than in women (0.1%). In multivariate analysis, male sex, history of intravenous drug abuse, and
imprisonment were signiﬁcantly associated with anti-HCV.
Conclusions: We found the prevalence of HCV infection in Iran to be higher than previous estimates. It
appears that the rate is rising, and in the future, hepatitis C will replace hepatitis B as the most common
cause of chronic viral liver disease in Iran.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Hepatitis C is the second most common chronic viral disease in
the world after hepatitis B.1 With the mass hepatitis B vaccination
programs now mandatory in many countries, it is predicted that
hepatitis C will emerge as the most common chronic viral liver
disease in the next few decades. Hepatitis C is already a major
cause of cirrhosis and hepatocellular carcinoma (HCC) and is a
leading cause of liver transplantation in the USA and many other
Western countries.2 The global prevalence of hepatitis C virus
(HCV) infection is at least 2%, with over 120 million infected.3 A
precise estimate of HCV prevalence is required for all prevention
and/or treatment programs. Most studies on HCV infection
prevalence have been performed on speciﬁc populations such as
blood donors, drug abusers, or cases of chronic hepatitis.* Corresponding author. Tel.: +98 21 8801 2992; fax: +98 21 8801 2992.
E-mail address: saeed_esmaili@hotmail.com (S. Esmaili).
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doi:10.1016/j.ijid.2009.11.032Population-based studies of HCV prevalence are not available
for many developing countries, including Iran.3 The ﬁrst study on
HCV prevalence in Iran was on healthy blood donors in 1994, and
showed a seroprevalence of 0.25%.4 In that year, blood donorswere
unselected and anyone was allowed to donate blood. This number
has always been stated as a rough estimate of the seroprevalence of
HCV in Iran. A more recent study, again on blood donors, indicated
an almost stable seroprevalence of 0.13% during the period of
2004–2007.5 It should be noted that blood donors are now selected
and that subjects with high risk factors are not allowed to donate
blood. Studies on blood donors are seriously affected by selection
bias and a male predominance. The male to female ratio is
occasionally as high as 10:1 in such reports. Reports on the
prevalence of HCV infection in special populations in Iran are as
high as 11–25% for patients on hemodialysis,6,7 11–52% for
intravenous drug abusers,8 and 15–76% for hemophilia and
thalassemia patients.9–12 In the current study, we present the
ﬁrst population-based data on the prevalence of HCV infection in
Iran.ses. Published by Elsevier Ltd. All rights reserved.
Table 2
Demographic data of the study populationa
Tehran Hormozgan Golestan Total
Subjects interviewed 2561 1987 2035 6583
Number valid 2561 1745 1896 6202
Samples collected 2326 1463 1895 5684
Male 41.6% 44.9% 31.9% 39.2%
Age, mean SD (years) 35.613.6 33.411.9 38.712.9 36.113.0
Rural 5.2% 0% 48.2% 18.2%
Currently married 68.2% 72.9% 86.9% 73.3%
History of blood transfusion 9.2% 2.0% 8.2% 6.8%
Addiction 3.7% 0.5% 14.5% 4.9%
Intravenous addiction 1.0% 0.1% N/A 0.7%
History of tattooing 7.8% 1.4% N/A 5.3%
History of imprisonment 1.7% 0.3% N/A 1.1%
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2.1. Study population
The general population of three provinces in Iran, Golestan (in
the north-east of Iran), Tehran (north-center), and Hormozgan
(south), was studied. Subjects between 18 and 65 years of agewere
included. Exclusion criteria were non-Iranian nationality, not
being a permanent inhabitant of the household, or not consenting
to the study. Some useful information on Iran and the three
provinces studied is given in Table 1.
2.2. Sampling and randomization
The study was performed as part of a larger study evaluating
common liver diseases in Iran during 2006. Clustered random
sampling was used. One hundred clusters were selected from each
province with a cluster size of 20 or 25. Postal code or family
registry code was used to randomly select the ﬁrst household for
each cluster. Blood samples were obtained from each subject and a
questionnaire was completed. The questionnaire included demo-
graphic and anthropometric data and risk factors for hepatitis. The
details of sampling and randomization are available elsewhere.13
2.3. Laboratory tests
Blood samples from each participant were transferred to the
Iran Blood Transfusion Organization (IBTO) Research Center where
they were tested for anti-HCV antibody (anti-HCV) using a third-
generation ELISA test (Ortho HCV 3.0 Enhanced SAVe ELISA, Ortho-
Clinical Diagnostics, Amersham, UK and Hepanostika HCV Ultrakit,
Beijing United Biomedical Co., Beijing, China). Positive samples
were re-tested and those positive in repeated ELISA were
conﬁrmed by a recombinant immunoblot assay (RIBA) test
(INNO-LIA HCV Score, Innogenetics, Ghent, Belgium). Subjects
with a positive RIBA test were considered to have true anti-HCV
and thus, exposure to the virus and active or past infection.
2.4. Statistical analysis
The prevalence of HCV infection was computed using a weight
equal to the proportion of the population in each province. The
same weights were used for evaluating frequencies for each risk
factor. Weighted logistic regression analyses were used to
calculate the odds ratio and 95% conﬁdence interval (OR
(95%CI)) for each risk factor. Then a ﬁnal logistic model was
developed by a backward model selection for age, sex, province,
marital status, history of transfusion, addiction, and imprison-
ment. The ﬁnal model was checked for outliers and goodness-of-
ﬁt.
2.5. Ethics
Written and informed consent was obtained from all subjects.
Data were stored in the database with no reference to the subjects’
names. The study protocol and the consent forms were reviewedTable 1
Census information—Iran and the three provinces studieda
Area (km2) Population Urban Male Literacy
Iran 1 648 195 70 495 782 68.5% 50.9% 84.0%
Tehran 18 814 13 422 366 91.3% 51.4% 91.3%
Hormozgan 70 697 1 403 674 47.1% 51.7% 82.4%
Golestan 20 367 1 617 087 49.2% 49.7% 82.1%
a Source: Iran national population and housing census, 2006; http://www.sci.or-
g.ir/portal/faces/public/sci_en, reproduced from Merat et al.13and approved by the Institutional Review Board of the Digestive
Disease Research Center, Tehran University of Medical Sciences.
3. Results
A total of 6583 subjects were interviewed in the three
provinces. The age criterion was not strictly observed in 381
subjects from Hormozgan and Golestan (age <18 or >65 years).
These subjects were deleted from the database and not analyzed
further. Another 518 subjects refused blood sampling or had
inadequate samples and were excluded. A signiﬁcantly higher
number of exclusions, as compared to included subjects, were from
Hormozgan Province (54.4% vs. 25.7%), lived in a rural area (94.4%
vs. 81.8%), and were male (45.9% vs. 39.2%). A signiﬁcantly lower
number of exclusions were from Golestan Province (0.2% vs.
33.3%). There was no signiﬁcant age difference between included
and excluded subjects. A total of 5684 samples were analyzed.
Demographic characteristics of the study population are given in
Table 2. The frequency of all the risk factors studied was
signiﬁcantly different between the three provinces.
One hundred and forty-two study subjects were positive for
anti-HCV by ELISA. Of these, 50were conﬁrmed by RIBA. The rate of
positive RIBA tests (seroprevalence) in the three provinces and
both sexes are given in Table 3. The age-speciﬁc seroprevalence of
HCV for each sex is indicated in Table 4. It can be seen that the
difference between the sexes ismost prominent in the younger age
groups.
In univariate analysis, Golestan and Hormozgan provinces had
signiﬁcantly higher rates of anti-HCV. Male sex, living in a rural
area, unmarried status, history of transfusion, drug abuse
(intravenous and non-intravenous), tattooing, and imprisonment
were also correlated with higher HCV infection rates (Table 5). In
multivariate analysis, only male sex, history of intravenous drug
abuse, and imprisonment remained signiﬁcantly associated with
anti-HCV (Table 6). Golestan subjects were excluded from the
multivariate analysis due to a high rate of missing data.
4. Discussion
This is the ﬁrst population-based study on the prevalence of
HCV infection in Iran. We observed an overall seroprevalence ofa Percentages reported for subjects with available data. N/A, data not available.
Table 3
The weighted seroprevalence of hepatitis C virus in three provinces of Iran (n (%))
Tehran Hormozgan Golestan Total
Total 8 (0.3%) 24 (1.6%) 18 (1.0%) 50 (0.5%)
Male 8 (0.8%) 17 (2.6%) 8 (1.3%) 33 (1.0%)
Female 0 (0.0%) 7 (0.9%) 10 (0.8%) 17 (0.1%)
Table 4
The weighted seroprevalence of hepatitis C virus in male and female subjects in
different age groups
Age group Male Female
18–29 years 1.2% 0.2%
30–45 years 0.9% 0.1%
46–65 years 0.4% 0.0%
Table 5
Risk factors associated with anti-HCV in univariate analysis
Number (%) OR (95% CI) p-Value
Province
Tehran 8 (0.3%) 1
Hormozgan 24 (1.6%) 4.8 (2.2–10.8) <0.001
Golestan 18 (1.0%) 3.0 (1.3–7.0) 0.011
Sex
Female 17 (0.1%) 1
Male 33 (1.0%) 10.2 (5.0–20.8) <0.001
Location
Urban 40 (0.4%) 1
Rural 10 (1.3%) 3.4 (1.1–10.7) 0.040
Age group (years)
18–29 20 (0.9%) 1
30–45 21 (1.1%) 0.6 (0.2–1.8) 0.4
46–65 9 (0.6%) 0.2 (0.1–0.6) 0.002
Educationa
<5 years 13 (0.6%) 1
5–12 years 14 (0.4%) 0.6 (0.2–1.8) 0.3
>12 years 4 (0.3%) 0.5 (0.1–3.0) 0.5
Marital statusa
Married 17 (0.2%) 1
Not married 15 (1.0%) 6.9 (2.4–19.9) <0.001
Transfusiona
No 30 (0.5%) 1
Yes 1 (0.1%) 0.1 (0.01–0.8) 0.028
Addictiona
No 26 (0.2%) 1
Yes 5 (5.8%) 27.4 (8.9–84.0) <0.001
Intravenous addictiona
No 28 (0.3%) 1
Yes 3 (12.9%) 49.4 (12.7–192.5) <0.001
Tattooinga
No 27 (0.3%) 1
Yes 4 (2.2%) 8.1 (2.5–26.2) 0.001
Imprisonmenta
No 26 (0.3%) 1
Yes 5 (10.4%) 45.3 (13.6–151.0) <0.001
a Data available for Tehran and Hormozgan Province only.
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(HBV), the rate for different provinces was signiﬁcantly different.
Considering the ethnic diversity and lifestyle variations among the
different provinces of Iran, which is also discernible from Table 2,
such a difference might be expected.13 The difference is quite
signiﬁcant in the case of Hormozgan. This province is located onTable 6
Risk factors associated with anti-HCV in multivariate analysisa
OR (95% CI) p-Value
Male sex 15.8 (4.8–51.7) <0.001
History of intravenous drug abuse 29.6 (2.2–401.0) 0.001
History of imprisonment 20.3 (2.9–141.7) 0.002
Hormozgan vs. Tehran 10.3 (4.4–23.9) <0.001
a Subjects from Golestan Province were excluded due to the large quantity of
missing data.the northern littoral of the Persian Gulf and only a few hours of
sailing from the Arab countries of the south. Much of the economy
of Hormozgan is based on frequent travel to these countries, which
might explain the greater exposure in this area. Another ﬁnding of
interest is the signiﬁcantly higher prevalence inmales as compared
to females. In the case of HBV, we observed that there was no
signiﬁcant sex preponderance after correcting for high-risk
behaviors,13 but the same does not appear to be true for HCV.
This might be related to the fact that the transmission of HBV has
been largely vertical, mother-to-infant, which is expected to infect
male and female infants equally. Conversely, the transmission of
HCV is through infected blood or blood products, needle sharing in
intravenous drug abusers, and sexual promiscuity.14 Male sex was
an independent predictor of HCV infection inmultivariate analysis.
We have no explanation for this ﬁnding except that drug abuse,
which is more common in men and was also found to be the
strongest predictor in our study, might have been under-reported
by our subjects. Alternatively, there might be other risk factors,
more common in males, which we have not sought. An important
ﬁnding is that the difference in sex is especially prominent in the
younger age groups (Table 4), which is not only indicative of
certain risk factors, but also indicates an important epidemiologic
identity of HCV in Iranian young and middle-aged men.
Unfortunately, previous reports from Iran have included very
few women, so we cannot reliably comment on changes in
prevalence in women. However, our data suggest that the rate in
women is fairly constant in the different age groups and that the
increased seroprevalence of HCV is mainly attributable to younger
males.
We also observed an increased prevalence of HCV among rural
subjects. A similar ﬁnding has also been reported for HBV.13 We
have no explanation for this ﬁnding other than the possible impact
of lower socioeconomic status and standards of general health in
these areas.
Our study conﬁrms the correlation of intravenous drug abuse
with HCV infection.14 We also found a highly signiﬁcant
correlation with imprisonment. Intravenous drug abuse is illegal
in Iran and addicts are imprisoned. Needle sharing, as well as
introduction to drug abuse, frequently occurs in prisons, which
might explain why imprisonment is an independent risk factor for
HCV infection.15 Realization of this fact by the Iranian Ministry of
Justice has led to harm-reduction policies, including separation of
intravenous drug addicts in prisons and the provision of free
needles and syringes. These efforts are still in their early stages, but
could reduce the transmission of HCV and other blood-borne
infections in our prisons.15
In univariate analysis, not being married, living in an urban
area, and history of transfusion or tattooing were also risk factors
for HCV infection, but they lost their signiﬁcance in multivariate
analysis, indicating that they are somehow dependant on other
factors. It should be noted that multivariate analysis was only
performed on subjects from Hormozgan and Tehran.
An important strength of our study is that approximately 60% of
our participants were women. Almost all previous studies,
including those on hemophiliacs, drug abusers, and blood donors,
have been performed on populations with an over 80% male
preponderance, and a valid prevalence for the female population of
Iran did not exist.
The seroprevalence of HCV among Iranian blood donors was
0.25% in 1994.4 In the current study we observed a rate of 0.5%.
Although our study is population-based and is not directly
comparable to blood-donor studies, it strongly suggests an
increase in the seroprevalence of HCV in Iran. The increasing
seroprevalence of HCV indicates that hepatitis C is gradually
replacing hepatitis B as themost common chronic viral hepatitis in
Iran.16,17
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approximately 2500 patients presenting to various referral centers,
55–64% of Iranian patients were found to carry the so called
difﬁcult-to-treat genotypes 1 and 4.18,19 Although alcohol con-
sumption is not common in Iran, obesity, insulin resistance, and
non-alcoholic steatohepatitis, all of which worsen the prognosis
and render it more difﬁcult to treat, are very common.20,21
A positive RIBA test conﬁrms the presence of anti-HCV and
exposure to thevirus.But this is notnecessarilyequivalent tochronic
hepatitis C infection, as only 60–85% of patients exposed to HCV
progress to chronicity.1,22 Reports from IBTO state that 70% of their
RIBA-positive anti-HCV cases are positive forHCVRNA (unpublished
data).Wehavenot tested for HCVRNA in our study, but based on the
reports from IBTO, it is safe to assume that at least 70% of our cases
would be HCV RNA positive. Therefore, the prevalence of chronic
hepatitis C in Iran would be 0.35% and the number of Iranians with
chronic hepatitis C about 250 000. It is estimated that almost 16% of
these patients will progress to cirrhosis over 20 years.23 Thus, if not
treated, we should expect at least 40 000 new cases of hepatitis C
cirrhosis by 2028. The medical costs of a cirrhotic patient are very
high and many would eventually require liver transplantation. The
cost of transplant and the following life-long immunosuppression is
tremendous. Even after transplant, the 100% recurrence rate of HCV
requires further treatment and frequently re-transplant. Many
studies point to the cost effectiveness of treating hepatitis C patients
before they progress to cirrhosis.24,25
In conclusion, the seroprevalence of HCV in the population
studied is 0.5%, which is higher than previous estimates for Iran. It
appears that the prevalence of HCV is rising, especially among
younger men, and in the future hepatitis C will replace hepatitis B
as the most common cause of chronic viral liver disease in Iran.
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